Phase II study of thalidomide in patients with metastatic melanoma

Melanoma Research

Volumn 14, Issue 1, 2004, Pages 57-62

  Pawlak, Wojciech Z ^a   Legha, Sewa S ^a  

^a St Luke's Medical Tower ^*

Author keywords

Antiangiogenesis; Cytostatic activity; Melanoma; Metastatic melanoma; Thalidomide

Indexed keywords

ALKALINE PHOSPHATASE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; AGED; AMNESIA; ANEMIA; ANGIOGENESIS; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRY EYE; DRY SKIN; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; LIVER TOXICITY; MALE; MELANOMA; METASTASIS; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOMNOLENCE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 1642361149     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200402000-00009     Document Type: Article

References (32)

1. Khayat D, Coeffic D, Antoine E-C. Overview of medical treatments of metastatic malignant melanoma. In: ASCO Educational Book. Alexandria: American Society of Clinical Oncology; 2000, 414-427.
2. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995; 9:1149-1158.
3. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002; 29:427-445.
4. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989; 64:2024-2029.
5. McClay EF, Mastrangelo MJ, Berd D, Bellet RE. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992; 50:553-556.
6. Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM, Benjamin RS. Clinical evaluation of recombinant Interferon alfa-2A (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 1987; 5:1240-1246.
7. Creagan ET, Schaid DJ, Ahmann DL, Frytak S. Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders. Am J Clin Oncol 1988; 11:652-659.
8. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-913.
9. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89-96.
10. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997; 24 (suppl 4):S39-S43.
11. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulous N. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996; 7:827-835.
12. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16:1752-1759.
13. Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20:2045-2052.
14. Pawlak W, Wcislo G, Langiewicz P, Surowinska J, Paprocka J, Duchnowska R, et al. Biochemotherapy of metastatic malignant melanoma (MMM) with CVD-BIO: a phase II study. Proc Am Soc Clin Oncol 2002; 21:352a (abstract 1404).
15. D'Amato RJ, Loughnan MS, Rynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
16. Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892.
17. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 72:339-343.
18. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the cell adhesion cascade. Immunopharmacology 1996; 31:213-221.
19. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001; 7:3349-3355.
20. Cavenagh JD, Oakervee H. The UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003; 120:18-26.
21. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
22. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002; 56:4-12.
23. Erhard H, Rietveld FJ, van Altena MC, Brocker EB, Ruiter DJ, de Waal RM. Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res 1997; 7 (suppl 2):S19-S26.
24. Bayko L, Rak J, Man S, Bicknell R, Ferrara N, Kerbel RS. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis 1998; 2:203-217.
25. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82:812-817.
26. Pavlick AC, Oratz R, Bailes A, Farrell K, Volm M, Muggia F. A phase II trial of DTIC with thalidomide in metastatic melanoma. Proc Am Soc Clin Oncol 2002; 21:349a (abstract 1393).
27. Hwu W-J, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, et al. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 2002; 21: 2610-2615.
28. Hwu W-J, Krown SE, Menell JH, Panageas KS, Merrell J, Quinn CJ, et al. Temozolomide (TMZ) plus thalidomide in patients with advanced melanoma: a phase II trial. Proc Am Soc Clin Oncol 2002; 21:344a (abstract 1372).
29. Danson S, Arance A, Lorigan P, Clamp A, Hodgetts J, Lomax L, et al. A randomized study of temozolomide (TMZ) alone, with interferon-alpha (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Proc Am Soc Clin Oncol 2002; 21:343a (abstract 1369).
30. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19:265-272.
31. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001; 19 (18 suppl): 45S-51S.
32. Schiller J. Early trials of antiangiogenic agents. Adv Oncol 1999; 15:3-10.